These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. [Endothelial mechanisms in vasomotor effects of ACE inhibitors]. Busse R; Hecker M Z Kardiol; 1994; 83 Suppl 4():1-6. PubMed ID: 7856274 [TBL] [Abstract][Full Text] [Related]
30. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats. Campbell DJ; Anastasopoulos F; Duncan AM; James GM; Kladis A; Briscoe TA J Pharmacol Exp Ther; 1998 Nov; 287(2):567-77. PubMed ID: 9808682 [TBL] [Abstract][Full Text] [Related]
31. Antihypertrophic effects of combined inhibition of the renin-angiotensin system (RAS) and neutral endopeptidase (NEP) in progressive, tachycardia-induced experimental heart failure. Birner C; Ulucan C; Bratfisch M; Götz T; Dietl A; Schweda F; Riegger GA; Luchner A Naunyn Schmiedebergs Arch Pharmacol; 2012 Nov; 385(11):1117-25. PubMed ID: 22895639 [TBL] [Abstract][Full Text] [Related]
32. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Linz W; Wiemer G; Gohlke P; Unger T; Schölkens BA Pharmacol Rev; 1995 Mar; 47(1):25-49. PubMed ID: 7784479 [TBL] [Abstract][Full Text] [Related]
33. Maximizing the natriuretic peptide system in experimental heart failure: subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition. Chen HH; Lainchbury JG; Harty GJ; Burnett JC Circulation; 2002 Feb; 105(8):999-1003. PubMed ID: 11864932 [TBL] [Abstract][Full Text] [Related]
34. Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition. Cruden NL; Fox KA; Ludlam CA; Johnston NR; Newby DE Hypertension; 2004 Dec; 44(6):913-8. PubMed ID: 15492133 [TBL] [Abstract][Full Text] [Related]
35. [Vasopeptidase inhibition: a new pharmacological principle in the treatment of hypertension and cardiac insufficiency]. Kolloch R; Offers E Dtsch Med Wochenschr; 2001 Nov; 126(47):1342-7. PubMed ID: 11719860 [No Abstract] [Full Text] [Related]
36. Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats. Gonzalez Vera W; Fournié-Zaluski MC; Pham I; Laboulandine I; Roques BP; Michel JB J Pharmacol Exp Ther; 1995 Jan; 272(1):343-51. PubMed ID: 7815350 [TBL] [Abstract][Full Text] [Related]
37. A computational approach to the study of the binding mode of dual ACE/NEP inhibitors. Dimitropoulos N; Papakyriakou A; Dalkas GA; Sturrock ED; Spyroulias GA J Chem Inf Model; 2010 Mar; 50(3):388-96. PubMed ID: 20170101 [TBL] [Abstract][Full Text] [Related]
38. Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure. Xu J; Carretero OA; Liu YH; Yang F; Shesely EG; Oja-Tebbe N; Yang XP J Card Fail; 2004 Feb; 10(1):83-9. PubMed ID: 14966779 [TBL] [Abstract][Full Text] [Related]
39. Inhibition of peptidases in the control of blood pressure. Kubota E; Dean RG; Balding LC; Burrell LM Essays Biochem; 2002; 38():129-39. PubMed ID: 12463166 [TBL] [Abstract][Full Text] [Related]